Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia

被引:19
|
作者
Branchi, A
Fiorenza, AM
Torri, A
Muzio, F
Berra, C
Colombo, E
Dalla Valle, E
Rovellini, A
Sommariva, D
机构
[1] Univ Milan, Osped Maggiore, IRCCS, Dipartimento Med Interna, I-20121 Milan, Italy
[2] G Salvini Hosp, Dept Internal Med, Milan, Italy
关键词
atorvastatin; simvastatin; high-density lipoprotein cholesterol; serum lipids;
D O I
10.1016/S0149-2918(01)80073-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Simvastatin 40 to 80 mg/d has been found to increase high-density lipoprotein cholesterol (HDL-C) levels significantly more than atorvastatin at equipotent doses (ie, 20-80 mg/d). Data on the effects of lower doses of the 2 drugs on HDL-C levels are conflicting. Objective: The purpose of this study was to investigate the effects of simvastatin 20 mg/d and atorvastatin 10 mg/d on HDL-C levels in patients with hypercholesterolemia. Methods: Patients with primary hypercholesterolemia (total cholesterol [TC] > 250 mg/dL) who were not taking any lipid-lowering agents and who were following a low-fat diet were randomized to receive 1 of 2 treatments: simvastatin 20 mg/d or atorvastatin 10 mg/d. Serum TC, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and HDL-C levels were measured using standard methods after 2 months of therapy. In a secondary analysis, lipids and lipoprotein cholesterol were measured after 1 year in patients who continued treatment. Results: OF the 240 patients enrolled (108 men and 132 women; age range, 23-77 years, mean [SEM] 56.7 [0.69]), 235 completed the study. After 2 months of therapy, TC, LDL-C, and serum TG levels decreased significantly versus baseline in both groups (P < 0.001), with no significant differences between treatment groups. HDL-C levels increased by 9.0% (P < 0.001 vs baseline) in the simvastatin group and by 4.3% (P < 0.02) in the atorvastatin group. The difference between the 2 groups in the percentage increase in HDL-C was statistically significant (P < 0.05). In 113 patients who continued treatment, HDL-C levels at 1 year were still significantly higher than baseline levels in the simvastatin group (6.3%, P = 0.034), but not in the atorvastatin group (2.8%, P = 0.587). Conclusions: The findings from this study suggest that the HDL-C-increasing effect of simvastatin 20 mg is significantly greater than that of atorvastatin 10 mg. Since increasing HDL-C levels is thought to lower the risk for atherosclerosis and coronary heart disease, these results warrant further investigation.
引用
收藏
页码:851 / 857
页数:7
相关论文
共 50 条
  • [31] A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance
    Sasaki, Jun
    Ikeda, Yoshihiko
    Kuribayashi, Tadanobu
    Kajiwara, Keizou
    Biro, Sadatoshi
    Yamamoto, Kyosuke
    Ageta, Masato
    Kobori, Syozou
    Saikawa, Tetsunori
    Otonari, Takatoshi
    Kono, Suminori
    CLINICAL THERAPEUTICS, 2008, 30 (06) : 1089 - 1101
  • [32] Low Levels of High-Density Lipoprotein Cholesterol Predict the Presence of Coronary Artery Disease in Patients With Aortic Aneurysms
    Saigusa, Tatsuya
    Izawa, Atsushi
    Miura, Takashi
    Ebisawa, Soichiro
    Shiba, Yuji
    Miyashita, Yusuke
    Tomita, Takeshi
    Koyama, Jun
    Fukui, Daisuke
    Takano, Tamaki
    Amano, Jun
    Ikeda, Uichi
    ANGIOLOGY, 2014, 65 (08) : 710 - 715
  • [33] The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia
    Florentin, Matilda
    Liberopoulos, Evangelos N.
    Moutzouri, Elisavet
    Rizos, Christos V.
    Tselepis, Alexandros D.
    Elisaf, Moses S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (03) : 685 - 692
  • [34] Treating low high-density lipoprotein cholesterol: what is the evidence?
    Hage, Mirella P.
    Azar, Sami T.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2014, 5 (01) : 10 - 17
  • [35] Low High-Density Lipoprotein Cholesterol and Chronic Disease Risk
    Robinson, Jennifer G.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (25) : 2855 - 2857
  • [36] Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome
    Robinson, Jennifer G.
    Ballantyne, Christie M.
    Hsueh, Willa A.
    Rosen, Jeffrey B.
    Lin, Jianxin
    Shah, Arvind K.
    Tomassini, Joanne E.
    Lowe, Robert S.
    Tershakovec, Andrew M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2013, 7 (04) : 292 - 303
  • [37] Evidence for low high-density lipoprotein cholesterol levels in Australian indigenous peoples: a systematic review
    Lyons, Jasmine G.
    O'Dea, Kerin
    Walker, Karen Z.
    BMC PUBLIC HEALTH, 2014, 14
  • [38] Evaluation of Monocyte to High-Density Lipoprotein Cholesterol and Neutrophil to High-Density Lipoprotein Cholesterol Ratios as Indicators of Inflammation in Patients with Celiac Disease
    Duzenli, Tolga
    Koseoglu, Derya
    Koseoglu, Huseyin
    ERCIYES MEDICAL JOURNAL, 2022, 44 (03) : 274 - 278
  • [39] Evidence for low high-density lipoprotein cholesterol levels in Australian indigenous peoples: a systematic review
    Jasmine G Lyons
    Kerin O’Dea
    Karen Z Walker
    BMC Public Health, 14
  • [40] Comparison of soymilk and probiotic soymilk effects on serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in diabetic Wistar rats
    Babashahi, Mina
    Mirlohi, Maryam
    Ghiasvand, Reza
    Azadbakht, Leila
    ARYA ATHEROSCLEROSIS, 2015, 11 : 88 - 93